Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

  • — 11 Dec, 2005
AudioMedica News
AudioMedica News
Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)
Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)
/

Dennis Slamon, UCLA School of Medicine, Los Angeles
It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast cancer – provided agents such as docetaxel and trastuzumab are also included, according to the findings of the BCIRG 006 trial reported at the San Antonio Breast Cancer Symposium.
COMMENT: Norman Wolmark, NSABP foundation, Pittsburg

[audio:https://www.audiomedica.com/podcasting/ajo_14.1/01.dennis_slamon.mp3]


Click here for all the interviews from San Antonio Breast Cancer Symposium 2005

You may also like...